Ketamine for reduction of Alcoholic Relapse (KARE)

KARE is a new and innovative multi-disciplinary project, and stands for “Ketamine for reduction of Alcoholic Relapse”.

This clinical trial explores the combined use of psychological therapy and a low dose of ketamine as a possible treatment for alcoholism. KARE is a multi-site project running in both the South West of England as well as London.

Severe alcohol use disorder affects nearly 4 million people in the UK, with devastating consequences to lives. Staying sober is key to reducing the harm that alcohol can do to physical and mental health. Unfortunately, treatments to help people stop drinking alcohol have been shown to be limited in their effectiveness, and people often return to drinking after only a short time of being sober.

If you would like to hear more about this trial or are interested in taking part, please contact us via one of the following methods:

Please note that this trial has now closed for recruitment.

More information about the MORE-KARE trial ia available here